Inhibition by roflumilast vs cilomilast of pulmonary leukocyte accumulation and TNFα release in a rat model of LPS-induced pulmonary neutrophilia Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
The JAK3 inhibitor CP-690550 is a potent anti-fibrosis agent in a murine model of pulmonary fibrosis induced by bleomycin Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012
Lidocaine effect on airway neutrophilia caused by LPS mice in vivo Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003
Inhaled CCR1 antagonist AZD4818 reduces leucocyte influx in the rat lipopolysaccharide (LPS) lung inflammation model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Cilomilast, a second generation phosphodiestease 4 inhibitor, in combination with PGE2 attenuates fMLP, IL-8 and cigarette smoke-induced effects on the mechanical and functional properties of neutrophils Source: Eur Respir J 2001; 18: Suppl. 33, 161s Year: 2001
Intrapleural injection of pentoxifylline, a TNFa blocker, inhibit the pleurodesis induced by talc and doxycycline Source: Eur Respir J 2004; 24: Suppl. 48, 558s Year: 2004
Roflumilast N-oxide, a PDE4 inhibitor, curbs bleomycin-induced lung fibroblast activation in vitro Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Roflumilast potently inhibits CXCL1 mediated neutrophil migration in COPD patients Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011
Roflumilast but not methylprednisolone inhibited cigarette smoke-induced pulmonary inflammation in guinea pigs Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006
Effect of L-NAME and AG on AHR induced by LPS intraperitoneal injection Source: Eur Respir J 2005; 26: Suppl. 49, 367s Year: 2005
Dose-dependent effects of muIL-13Rα2, a potent IL-13 neutraliser, on the phenotype of an acute allergic airways inflammation model in BALB/c mice Source: Annual Congress 2004 - Animal models of asthma and chronic bronchitis and their relevance in pulmonary pharmacology Year: 2004
Effect of piclamilast, a selective phosphodiesterase (IV)-inhibitor, theophylline and prednisolone, on sputum cell and blood neutrophil oxidative burst from mild asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
IL-1β-induced MCP-1 production in human airway smooth muscle cells, modulation by dexamethasone, rolipram, and salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 353s Year: 2001
SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects Source: Eur Respir J 2010; 35: 564-570 Year: 2010
SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects Source: Annual Congress 2007 - New drugs for COPD Year: 2007
AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015